1. Home
  2. CRDO vs BIIB Comparison

CRDO vs BIIB Comparison

Compare CRDO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credo Technology Group Holding Ltd

CRDO

Credo Technology Group Holding Ltd

HOLD

Current Price

$175.72

Market Cap

34.2B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.61

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDO
BIIB
Founded
2008
1978
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2B
24.2B
IPO Year
2022
1991

Fundamental Metrics

Financial Performance
Metric
CRDO
BIIB
Price
$175.72
$181.61
Analyst Decision
Strong Buy
Buy
Analyst Count
12
23
Target Price
$179.91
$176.48
AVG Volume (30 Days)
7.1M
1.9M
Earning Date
12-01-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.11
10.97
Revenue
$796,128,000.00
$10,065,900,000.00
Revenue This Year
$127.02
$3.61
Revenue Next Year
$28.18
N/A
P/E Ratio
$158.36
$16.52
Revenue Growth
224.17
4.77
52 Week Low
$29.09
$110.04
52 Week High
$213.80
$185.17

Technical Indicators

Market Signals
Indicator
CRDO
BIIB
Relative Strength Index (RSI) 57.44 72.92
Support Level $176.00 $174.53
Resistance Level $213.80 $182.94
Average True Range (ATR) 13.80 5.22
MACD 3.38 0.25
Stochastic Oscillator 58.31 83.54

Price Performance

Historical Comparison
CRDO
BIIB

About CRDO Credo Technology Group Holding Ltd

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: